Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The right dose for every patient: a key step for precision medicine

Nature Reviews Drug Discovery volume 15, pages 145–146 (2016)Cite this article

Subjects

Abstract

Understanding the basis of variability in the response of patients to the dose of a drug and a willingness to vary the dose regimen as well as the choice of drug should be one of the key pillars of precision medicine.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bel, E. H. et al. Oral glucocorticoid sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371, 1189–1197 (2014).

    Article  Google Scholar 

  2. Yang, J. et al. The combination of exposure-response and case-control analyses in regulatory decision making. J. Clin. Pharmacol. 52, 160–166 (2012).

    Google Scholar 

  3. Wang, J. et al. Exposure–response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clin. Pharm. Ther. 95, 558–564 (2014).

    Article  CAS  Google Scholar 

  4. Ohtsu, A. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29, 3968–3976 (2011).

    Article  CAS  Google Scholar 

  5. Grahnen, A. & Karlsson, M. O. Concentration-controlled or effect-controlled clinical trials. Useful alternatives to conventional dose-controlled trials? Clin. Pharmacokinet. 40, 317–325 (2001).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Global Head of Clinical Pharmacology, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann La Roche Ltd, Grenzacherstrasse 124, Basel, 4070, Switzerland

    Richard W. Peck

Authors
  1. Richard W. Peck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard W. Peck.

Ethics declarations

Competing interests

R.W.P. is an employee of F. Hoffman la Roche. He holds stock and options in F. Hoffman la Roche and stock in Eli Lilly and Company Ltd.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peck, R. The right dose for every patient: a key step for precision medicine. Nat Rev Drug Discov 15, 145–146 (2016). https://doi.org/10.1038/nrd.2015.22

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2015.22

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research